Patent · US Active

Crystalline forms of a triazolopyrimidine compound

US11091489B2 · kind B2 · utility

0Cited by

6References

11Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Ying-Huey Huang · Taipei, TW
Bo Liu · San Diego, US
Liang Mao · Shanghai, CN
Long WANG · Shanghai, CN
Liladhar Murlidhar Waykole · East Hanover, US
Lijun Zhang · Los Altos Hills, US

Key dates

Filing date	Jun 19, 2017
Grant date	Aug 17, 2021
Priority date	—
Expiry date	Aug 7, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.